JP2022548071A5 - - Google Patents

Info

Publication number
JP2022548071A5
JP2022548071A5 JP2022516237A JP2022516237A JP2022548071A5 JP 2022548071 A5 JP2022548071 A5 JP 2022548071A5 JP 2022516237 A JP2022516237 A JP 2022516237A JP 2022516237 A JP2022516237 A JP 2022516237A JP 2022548071 A5 JP2022548071 A5 JP 2022548071A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
metformin
retinal
acceptable salt
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022516237A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022548071A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/050540 external-priority patent/WO2021050980A1/en
Publication of JP2022548071A publication Critical patent/JP2022548071A/ja
Publication of JP2022548071A5 publication Critical patent/JP2022548071A5/ja
Pending legal-status Critical Current

Links

JP2022516237A 2019-09-13 2020-09-11 網膜変性を治療するための新薬の開発につながる標的 Pending JP2022548071A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962899899P 2019-09-13 2019-09-13
US62/899,899 2019-09-13
PCT/US2020/050540 WO2021050980A1 (en) 2019-09-13 2020-09-11 Druggable target to treat retinal degeneration

Publications (2)

Publication Number Publication Date
JP2022548071A JP2022548071A (ja) 2022-11-16
JP2022548071A5 true JP2022548071A5 (https=) 2023-09-20

Family

ID=72644998

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022516237A Pending JP2022548071A (ja) 2019-09-13 2020-09-11 網膜変性を治療するための新薬の開発につながる標的

Country Status (10)

Country Link
US (1) US20220339127A1 (https=)
EP (1) EP4027985A1 (https=)
JP (1) JP2022548071A (https=)
KR (1) KR20220070232A (https=)
CN (1) CN114650813A (https=)
AU (1) AU2020346064A1 (https=)
BR (1) BR112022004515A2 (https=)
CA (1) CA3151011A1 (https=)
MX (1) MX2022003027A (https=)
WO (1) WO2021050980A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7505912B2 (ja) * 2020-04-30 2024-06-25 小林製薬株式会社 オートファジー活性化剤
WO2022023956A1 (en) * 2020-07-31 2022-02-03 The Joan and Irwin Jacobs Technion-Cornell Institute System and method for on-phase microscopy
KR102629963B1 (ko) * 2021-09-23 2024-01-29 순천향대학교 산학협력단 mTOR 활성화제를 포함하는 안질환 치료용 조성물 및 이의 용도
CN115969844B (zh) * 2021-12-28 2024-04-02 首都医科大学附属北京同仁医院 Nox2特异性抑制剂在制备视网膜变性药物中的应用
US20250170143A1 (en) * 2022-04-14 2025-05-29 Mayo Foundation For Medical Education And Research Methods of treating ocular fibrotic pathologies
CN115068456A (zh) * 2022-05-18 2022-09-20 中山大学中山眼科中心 二甲双胍在制备预防、治疗眼部疾病的药物中的用途及其剂型和制备方法
WO2023229993A1 (en) * 2022-05-25 2023-11-30 Curative Biotechnology, Inc. Ophthalmic formulation capable of delivering metformin to choroid rpe and retina
KR20230169735A (ko) 2022-06-09 2023-12-18 에스케이온 주식회사 배터리용 볼트 및 배터리 모듈
WO2024196814A1 (en) 2023-03-17 2024-09-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for treatment of age-related macular degeneration
EP4559900A1 (en) * 2023-11-21 2025-05-28 Opus Genetics, Inc. Phentolamine mesylate and therapeutic uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
CN1704048A (zh) * 2004-05-25 2005-12-07 孙明杰 复方羟苯磺酸钙
US20060257391A1 (en) * 2005-05-11 2006-11-16 Bausch & Lomb Incorporated Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions
WO2008022256A2 (en) * 2006-08-16 2008-02-21 Blagosklonny Mikhail V Methods and compositions for preventing or treating age-related diseases
JP2010047567A (ja) * 2008-07-24 2010-03-04 Santen Pharmaceut Co Ltd 加齢黄斑変性の予防又は治療剤
KR101498665B1 (ko) * 2013-01-10 2015-03-05 한국 한의학 연구원 천연 추출물을 포함하는 당뇨합병증 또는 혈관부종의 예방 또는 치료용 약학적 조성물 및 건강기능식품 조성물
WO2014152661A1 (en) * 2013-03-14 2014-09-25 Panoptica, Inc. Ocular formulations for drug-delivery to the posterior segment of the eye
WO2015103480A1 (en) * 2014-01-02 2015-07-09 Massachusetts Eye & Ear Infirmary Treating ocular neovascularization
CA2976632A1 (en) * 2015-02-13 2016-08-18 Stealth Biotherapeutics Corp Therapeutic compositions including mitochondrial fission inhibitor peptides, variants thereof and methods of using the same
US20200056186A1 (en) * 2016-09-22 2020-02-20 Rsem, Limited Partnership Compositions comprising sasp modulators and senescence attenuators and uses thereof for modulating cellular senescence
WO2019033119A1 (en) * 2017-08-11 2019-02-14 Unity Biotechnology, Inc. TREATMENT OF OPHTHALMIC CONDITIONS SUCH AS MACULAR DEGENERATION, GLAUCOMA AND DIABETIC RETINOPATHY USING PHARMACEUTICAL AGENTS THAT ELIMINATE SENESCENT CELLS
WO2019108602A1 (en) * 2017-11-28 2019-06-06 University Of Florida Research Foundation Methods and compositions for retinal drug delivery

Similar Documents

Publication Publication Date Title
JP2022548071A5 (https=)
JP7519413B2 (ja) 眼科用薬剤組成物、眼科用キット、及びその医学的応用
PL211870B1 (pl) Zastosowanie roflumilastu i jego pochodnych w leczeniu zespołu suchego oka oraz oftalmologiczny preparat farmaceutyczny w postaci kropli do oczu
Abadia et al. Clinical applications of dexamethasone for aged eyes
JP2011500568A (ja) 眼病治療のための組成物及び方法
JP2009501797A5 (https=)
CN111372576A (zh) 用于治疗眼部病症的组合物和方法
JP2021519753A5 (https=)
RU2017112930A (ru) Офтальмологические составы для доставки лекарств и защиты переднего отдела глаза
JP2022525007A5 (https=)
Khan et al. Recent updates on drug delivery approaches for improved ocular delivery with an insight into nanostructured drug delivery carriers for anterior and posterior segment disorders
JP2003522160A5 (https=)
US20180207091A1 (en) Novel methods for delivering therapeutic agents to the eye via nasal passages
FI3720428T3 (fi) Dobesiliinihappoa käsittävä oftalminen paikalliskoostumus silmän takasegmentin sairauksien hoitoon
CN111315369A (zh) 用于治疗眼部病症和皮肤疾病的化合物、组合物和方法
CN106999452B (zh) 前列腺素类和一氧化氮供体的组合产品
JP2011518875A5 (https=)
WO2007075720A8 (en) Topical mecamylamine formulations for ocular administration and uses thereof
JP2013513606A5 (https=)
Basu et al. Modified thiomer-based nanomedicines in management of ocular complications: a review
JP7829678B2 (ja) 神経変性眼疾患を治療するためのプリドピジン及びその類似体
TW202034918A (zh) 治療眼睛病況之方法及組合物
JP2005515992A5 (https=)
JP2025511845A5 (https=)
Natesan et al. Chitosan-based ocular drug delivery systems